With its stock down 12% over the past three months, it is easy to disregard Johnson & Johnson (NYSE:JNJ). However, stock ...

Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Shares of Johnson & Johnson JNJ slid 0.27% to $146.24 Thursday, on what proved to be an all-around rough trading session for ...

BofA Securities has recently resumed Johnson & Johnson (JNJ) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

Johnson & Johnson (JNJ) stock saw a decline, ending the day at $149.23 which represents a decrease of $-0.37 or -0.25% from the prior close of $149.6. The stock opened at $149.93 and touched a low of ...

and Johnson & Johnson. Rishabh Mishra Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program Bristol Myers Squibb sues HRSA, claiming its rejection of a ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

New Brunswick, New Jersey-based Johnson & Johnson (JNJ), researches, develops, manufactures, and sells various healthcare ...

This was the stock's second consecutive day of losses.

Johnson & Johnson (JNJ) closed the most recent trading day at $149.23, moving -0.25% from the previous trading session. This change was narrower than the S&P 500's daily loss of 0.3%. At the same time ...

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $176.92, representing a 20.98% upside. In a report released on December 11, Citi also maintained ...

Analysts at Zacks Research reduced their Q2 2025 earnings estimates for shares of Johnson & Johnson in a research note issued ...